ABBV – AbbVie Stock: AbbVie Inc, a global biopharmaceutical company, focuses on developing and monetizing treatments within immunology, oncology, and neuroscience. For investors, predicting its stock trends is crucial to determine its potential as a future investment. This article reviews AbbVie’s stock analysis from 2025 to 2030, examining its financial achievements, market tendencies, and growth potential.
Founded in 2012 as a spin-off from Abbott Laboratories, AbbVie quickly became an industry titan. It is best known for Humira, a leading immunology treatment, and has also pioneered other treatments like Rinvoq and Skyrizi1. With a rich pipeline of products and the acquisition of Allergan, AbbVie has diversified its offerings across various therapy categories.
AbbVie (ABBV) Company Overview
| Company Name | AbbVie (ABBV) Inc. |
| Founded | 2012 |
| Headquarters | North Chicago, Illinois, United States |
| Industry | Biopharmaceutical |
| Chairman | Richard A. Gonzalez |
| Stock Exchange Listing | NYSE, S&P |
| Official Website | abbvie.com |
AbbVie (ABBV) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Cap | $318.08B |
| ROE | — |
| P/E | 52.7 |
| P/B | 52.1 |
| Div. Yield | 3.64% |
| Book Value | — |
| EPS (TTM) | $1.00 |
| 52 Week High | $207.32 |
| 52 Week Low | $153.58 |
Also Read: NVIDIA Stock Price Prediction
AbbVie (ABBV) Financials
Income Statement
| (USD) | 2023 | Y/Y change |
|---|---|---|
| Revenue | 54.32B | -6.44% |
| Operating expense | 19.93B | 7.33% |
| Net income | 4.86B | -58.91% |
| Net profit margin | 8.95 | -56.11% |
| Earnings per share | 11.11 | -19.32% |
| EBITDA | 26.36B | -16.12% |
| Effective tax rate | 22.03% | — |
Balance Sheet
| (USD) | 2023 | Y/Y change |
|---|---|---|
| Cash and short-term investments | 12.82B | 38.87% |
| Total assets | 134.71B | -2.95% |
| Total liabilities | 124.31B | 2.30% |
| Total equity | 10.40B | — |
| Shares outstanding | 1.77B | — |
| Price to book | 30.39 | — |
| Return on assets | 8.07% | — |
| Return on capital | 14.44% | — |
Cash Flow
| (USD) | 2023 | Y/Y change |
|---|---|---|
| Net income | 4.86B | -58.91% |
| Cash from operations | 22.84B | -8.44% |
| Cash from investing | -2.01B | -222.47% |
| Cash from financing | -17.22B | 30.56% |
| Net change in cash | 3.61B | 762.94% |
| Free cash flow | 22.63B | -1.47% |
Also Read: JP Morgan Stock Price Forecast
ABBV- AbbVie Stock Price Forecast From 2025 to 2030
| Year | Target Price |
|---|---|
| AbbVie Stock Price Forecast 2025 | $220 |
| AbbVie Stock Price Forecast 2026 | $260 |
| AbbVie Stock Price Forecast 2027 | $280 |
| AbbVie Stock Price Forecast 2028 | $340 |
| AbbVie Stock Price Forecast 2029 | $310 |
| AbbVie Stock Price Forecast 2030 | $400 |
AbbVie (ABBV) Top Shareholders
| Investor | Ownership Percentage |
|---|---|
| Vanguard Fiduciary Trust Co. | 9.713% |
| BlackRock Advisors LLC | 5.988% |
| State Street Corp. | 4.474% |
| JPMorgan Investment Management, Inc. | 2.939% |
| Eaton Vance Management | 2.190% |
| Capital Research & Management Co. (International Investors) | 2.082% |
| Geode Capital Management LLC | 2.046% |
| Capital Research & Management Co. (Global Investors) | 1.879% |
| BlackRock Life Ltd. | 1.542% |
| Charles Schwab Investment Management, Inc. |
Also Read: Devon Energy Stock Price Forecast
AbbVie (ABBV) Competitors/Peer Companies
- UnitedHealth Group Incorporated
- Novo Nordisk A/S
- Johnson & Johnson
- Merck & Co Inc
- AstraZeneca PLC
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Novartis AG
- Intuitive Surgical Inc
- Danaher Corp
Also Read: AMZN – Amazon Stock Price Forecast
To connect with us, click on any of the given social media buttons.
FAQs
-
What is AbbVie (ABBV) Stock Price Prediction for 2025?
220 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2026?
260 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2027?
280 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2029?
310 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2030?
400 USD.
Disclaimer: The information in this blog is for educational purposes only, and the targets mentioned in it are given as suggestions by market analysts. Therefore, before investing your money in any company, it is mandatory to get complete information about the company and consult your financial advisor.
